The online version of this article (https://doi.org/10.1007/s10549-018-4783-1) contains supplementary material, which is available to authorized users.
To provide an overview of clinical data supporting the use of cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), metastatic breast cancer (mBC), from the perspective of the practicing oncologist community.
A recent roundtable discussion was convened by The Breast Cancer Therapy Expert Group (BCTEG) to review existing data on this topic and its impact on their current practice.
Level 1 evidence now supports use of a CDK 4/6 inhibitor in combination with endocrine therapy for patients with HR+, HER2−, mBC. Currently, there are no biomarkers that reliably define patients who will, or will not, benefit from the addition of a CDK 4/6 inhibitor to their endocrine therapy. Additional research is needed to identify the optimal sequencing of CDK 4/6 inhibitors in relation to other therapies as well as the optimal duration of therapy; at present, evidence suggests that use in the upfront setting is better than waiting for a later line of therapy, or adding after endocrine therapy has started.
Thus far, three CDK 4/6 inhibitors—palbociclib, ribociclib, and more recently, abemaciclib—have been approved for use in the setting of HR+, HER2−, mBC. The degrees to which these agents differ in terms of CDK4/6 affinity, side-effect profiles, dosing, degree of central nervous system (CNS) penetration, optimal use in combination with antiestrogen therapy, and across other subsets of breast cancer, remain an active area of investigation.
Supplementary material 1 (DOCX 12 kb)10549_2018_4783_MOESM1_ESM.docx
Abraham J, Caldera H, Coleman R et al Breast Cancer Therapy Expert Group (BCTEG) (2018) Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Res Treat. https://doi.org/10.1007/s10549-018-4662-4669 CrossRef
Finn RS, Crown JP, Lang I et al (2015) The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25–35. https://doi.org/10.1016/S1470-2045(14)71159-3 CrossRefPubMed
Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M (2015) Cristofanilli M; PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373(3):209–219. https://doi.org/10.1056/NEJMoa1505270 CrossRefPubMed
Cristofanilli M, Turner NC, Bondarenko I et al (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17(4):425–439. https://doi.org/10.1016/S1470-2045(15)00613-0 CrossRefPubMed
Dickler MN, Tolaney SM, Rugo HS et al (2017) MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)/HER2(−) metastatic breast cancer. Clin Cancer Res 23(17):5218–5224. https://doi.org/10.1158/1078-0432.CCR-17-0754 CrossRefPubMedPubMedCentral
Di Leo A, Toi M, Campone M, et al. (2017) MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2− advanced breast cancer, Ann Oncol, 2017. https://doi.org/10.1093/annonc/mdx365 [Abstract 236O]
Tripathy D, Sohn J, Im S-A, et al. (2017) First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial. San Antonio Breast Cancer Symposium 2017. Abstract GS2-05
ASCO Post: FDA Approves New CDK4/6 Inhibitor for Certain Advanced or Metastatic Breast Cancers. http://www.ascopost.com/News/58090?utm_medium=Email&utm_source=ExactTarget&utm_campaign=&utm_term=7064487 Accessed 24 Nov 2017
Wardell SE, Ellis MJ, Alley HM et al (2015) Efficacy of SERD/SERM Hybrid-CDK4/6 inhibitor combinations in models of endocrine therapy-resistant breast cancer. Clin Cancer Res 21(22):5121–5130. https://doi.org/10.1158/1078-0432.CCR-15-0360 CrossRefPubMedPubMedCentral
Turner NC, Jiang Y, O’Leary B, et al. (2016) Efficacy of palbociclib plus fulvestrant (P + F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). J Clin Oncol 34(15_suppl):512–512
Finn RS, Crown J, Lang I, et al. (2017) Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2− advanced breast cancer (PALOMA-1; TRIO-18). J Clin Oncol 35:(15_suppl):1001–1001
Verma S, O’Shaughnessy J, Burris HA et al (2017) Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole. J Clin Oncol 35:1020–1020. https://doi.org/10.1200/jco.2017.35.15_suppl.1020 CrossRef
IBRANCE ® (palbociclib) capsules. Prescribing information. Revised 4/2017. Pfizer, Inc. New York, NY
Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ (2016) Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). Breast Cancer Res Treat 158(1):51–57. https://doi.org/10.1007/s10549-016-3822-z CrossRefPubMed
Raphael J, Helou J, Pritchard KI, Naimark DM (2017) Palbociclib in hormone receptor -positive advanced breast cancer: a cost-utility analysis. Eur J Cancer 85:146–154. https://doi.org/10.1016/j.ejca.2017.08.018 CrossRefPubMed
Malorni L, Curigliano G, Minisini AM, et al. (2017) A phase II trial of the CDK4/6 inhibitor palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2−) metastatic breast cancer (mBC) (TREnd trial). J Clin Oncol 35 (suppl; abstr 1002)
Infante JR, Shapiro G, Witteveen P, Gerecitano JF, Ribrag V, Chugh R et al (2014) A phase I study of the singleagent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. J Clin Oncol 32(15_suppl):2528–2528
Kornblum NS, Manola J, Klein P et al (2017) PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy. Cancer Res. https://doi.org/10.1158/1538-7445.sabcs16-s1-02 CrossRef
Cognetti F, Malaguti P, Alesini D (2016) Palbociclib: efficacious but predictive biomarkers still needed. Lancet Oncol 17(4):402–403. https://doi.org/10.1016/S1470-2045(16)00144-3 CrossRefPubMed
KISQALI ® (ribociclib) tablets. Prescribing information. Novartis Pharmaceuticals Corporation. East Hanover, New Jersey
VERZENIO™ (abemaciclib) tablets. Prescribing information. Eli Lilly and Company, Indianapolis
- Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)
Frankie Ann Holmes
E. Terry Mamounas
The Breast Cancer Therapy Expert Group (BCTEG)
- Springer US
Neu im Fachgebiet Onkologie
Mail Icon II